TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8968303

Group type: EXPERIMENTAL
Intervention: Fluoxetine 30 mg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 114
Study: 1359846

Group type: EXPERIMENTAL
Intervention: 500-mg daily dose of zidovudine
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: 1500-mg daily dose of zidovudine
Number of subjects: 1567

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: Zidovudine (both doses)
Number of subjects: 1567
Study: 3925770

Group type: EXPERIMENTAL
Intervention: Ciba transdermal nitroglycerin placebo patch
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transdermal patches (Ciba, Key, Searle)
Number of subjects: 80
Study: 30623228

Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29733836

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 68
Study: 27404184

Group type: EXPERIMENTAL
Intervention: Patient navigation only
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Patient navigation plus financial incentives
Number of subjects: 801

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 801
Study: 24668103

Group type: EXPERIMENTAL
Intervention: Web-based alcohol screening and brief intervention (10 minutes of assessment and feedback)
Number of subjects: 3422

Group type: COMPARATOR
Intervention: Control group (screening alone)
Number of subjects: 3422
Study: 22785499

Group type: EXPERIMENTAL
Intervention: Cell therapy group (n = 7; CABG and injection of bone marrow mononuclear cells (BMNCs) within MI areas)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (n = 7; CABG alone)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cell therapy group (n = 7)
Number of subjects: 14
Study: 19959322

Group type: EXPERIMENTAL
Intervention: Statin Choice decision aid
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual primary care visit without Statin Choice tool
Number of subjects: 150
Study: 17693444

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 8 weeks
Number of subjects: 64
Study: 15809394

Group type: EXPERIMENTAL
Intervention: Alcohol hand sanitizer
Number of subjects: 2932

Group type: COMPARATOR
Intervention: Traditional antiseptic handwash
Number of subjects: 2932
Study: 12749424

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) injection of 10,000 IU of hCG
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) injection of 10,000 IU of hCG
Number of subjects: 40
Study: 10707441

Group type: EXPERIMENTAL
Intervention: Alcohol-priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-alcohol priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 8706443

Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol administered vaginally every 12 hours, up to four times
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 400 micrograms of misoprostol administered vaginally every 12 hours, up to four times
Number of subjects: 234
Study: 1921255

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (120 mmol potassium per day with 50% citrate and 50% bicarbonate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6810736

Group type: EXPERIMENTAL
Intervention: Merck 20‐micrograms hepatitis B virus (HBV) vaccine
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study: 30362649

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold storage (CS)
Number of subjects: 20
Study: 28657799

Group type: COMPARATOR
Intervention: Traditional IPC (4×5-min legs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unilateral IPC (4×5-min legs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Remote IPC
Number of subjects: 12

Group type: COMPARATOR
Intervention: 8×5-min IPC
Number of subjects: 12
Study: 27071072

Group type: EXPERIMENTAL
Intervention: Hotspot-targeted interventions (larviciding, distribution of long-lasting insecticide-treated nets, indoor residual spraying, focal mass drug administration)
Number of subjects: 2042

Group type: COMPARATOR
Intervention: Control group (malaria control following Kenyan national policy)
Number of subjects: 2042

Group type: EXPERIMENTAL
Intervention: Hotspot-targeted interventions
Number of subjects: 2042
Study: 24452658

Group type: EXPERIMENTAL
Intervention: Local anesthetic only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local anesthetic mixed with betamethasone
Number of subjects: 120
Study: 22876835

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal therapeutic system (Bup‐TTS) 17.5 μg/h
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal therapeutic system (Bup‐TTS) 35 μg/h
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal therapeutic system (Bup‐TTS) 52.5 μg/h
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal therapeutic system (Bup‐TTS)
Number of subjects: 45
Study: 21133003

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection and pneumatic dilation (BT+PD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pneumatic dilation (PD)
Number of subjects: 34
Study: 17715139

Group type: COMPARATOR
Intervention: Ondansetron 0.1 mg kg(‐1)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.5 mg kg(‐1)
Number of subjects: 557
Study: 15253175

Group type: EXPERIMENTAL
Intervention: Support received during diagnosis and treatment
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Support received by families of women with breast cancer
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Primary sources of support
Number of subjects: 544
Study: 11684527

Group type: EXPERIMENTAL
Intervention: CP‐DC diet (22 g cocoa powder and 16 g dark chocolate)
Number of subjects: 23

Group type: COMPARATOR
Intervention: AAD (average American diet)
Number of subjects: 23
Study: 9856424

Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 7926968

Group type: EXPERIMENTAL
Intervention: Corticosteroids (either alone or associated with alpha-interferon)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alpha-interferon
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alpha-interferon + corticosteroids
Number of subjects: 21

Group type: COMPARATOR
Intervention: Untreated subjects
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Phorbol myristate acetate (PMA) treatment
Number of subjects: 21
Study: 2478048

Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg im)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fentanyl (100 micrograms iv)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oxymorphone (1 mg iv)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 150
Study: 772660

Group type: EXPERIMENTAL
Intervention: Isoxsuprine hydrochloride (Duvadilan Retard)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31388937

Group type: EXPERIMENTAL
Intervention: Preoperative biopsy showing DCIS with palpable lump
Number of subjects: 606

Group type: COMPARATOR
Intervention: Preoperative biopsy showing DCIS without palpable lump
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Preoperative biopsy showing DCIS with necrosis
Number of subjects: 606

Group type: COMPARATOR
Intervention: Preoperative biopsy showing DCIS without necrosis
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: 14G core-needle biopsy
Number of subjects: 606

Group type: COMPARATOR
Intervention: 9G vacuum-assisted biopsy
Number of subjects: 606
Study: 28059869

Group type: EXPERIMENTAL
Intervention: Longitudinal supra‐inguinal fascia iliaca compartment block with 40‐mL ropivacaine 0.5%
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 88
Study: 26083360

Group type: EXPERIMENTAL
Intervention: Intermittent cycles of remote ischemic preconditioning (IPC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 40
Study: 23689115

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) plus intravitreal bevacizumab (IVB) injections
Number of subjects: 42

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) alone
Number of subjects: 42
Study: 21640613

Group type: EXPERIMENTAL
Intervention: ND-ind group (n = 30)
Number of subjects: 120

Group type: COMPARATOR
Intervention: ND >110 group (n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DM-30 group (n = 30)
Number of subjects: 120

Group type: COMPARATOR
Intervention: DM-60 group (n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall results for diabetics and nondiabetics
Number of subjects: 120
Study: 19784815

Group type: COMPARATOR
Intervention: Short balloon inflation (deflated immediately after imaging at 14 atm)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Long balloon inflation (60 s at 14 atm)
Number of subjects: 92
Study: 17019290

Group type: EXPERIMENTAL
Intervention: Masai Barefoot Technology (MBT) shoe
Number of subjects: 123

Group type: COMPARATOR
Intervention: High-end walking shoe (control)
Number of subjects: 123
Study: 15134316

Group type: EXPERIMENTAL
Intervention: Not On Tobacco (N‐O‐T) program
Number of subjects: 258

Group type: COMPARATOR
Intervention: 15‐min single‐dose brief intervention
Number of subjects: 258
Study: 11375808

Group type: EXPERIMENTAL
Intervention: Milrinone (50 micro/kg) administered through the bypass pump 10 min before aortic cross-clamping
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9404430

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (specifics not provided)
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Previously treated patients or patients with cardiovascular complications
Number of subjects: 2250
Study: 8495453

Group type: EXPERIMENTAL
Intervention: Diclofenac-K 50 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diclofenac-K 100 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 3103663

Group type: EXPERIMENTAL
Intervention: alfentanil plus etomidate
Number of subjects: 44

Group type: COMPARATOR
Intervention: fentanyl plus thiopentone
Number of subjects: 44
Study: 30844477

Group type: EXPERIMENTAL
Intervention: Ginger supplementation (1500 mg daily for 12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 29085257

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: sANSWERS
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: GPA, ANSWERS, PoPLR
Number of subjects: 373
Study: 25313450

Group type: EXPERIMENTAL
Intervention: Healthy Weight (HW) intervention - 4 telephone coaching sessions on weight and physical activity
Number of subjects: 313

Group type: COMPARATOR
Intervention: Physical Activity (PA) intervention - 2 telephone coaching sessions on physical activity
Number of subjects: 313
Study: 23137828

Group type: EXPERIMENTAL
Intervention: Exercise (60 min run at 72% of VO(2)max)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10
Study: 20962652

Group type: EXPERIMENTAL
Intervention: General anaesthesia with sevoflurane (group S)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia with propofol (group P)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural anaesthesia (group E)
Number of subjects: 60
Study: 19085787

Group type: EXPERIMENTAL
Intervention: Thrombophilic defects present in NAION patients
Number of subjects: 76

Group type: COMPARATOR
Intervention: Thrombophilic defects present in controls
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High levels of factor VIII
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High levels of lipoprotein (a)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Patients without cardiovascular risk factors
Number of subjects: 76
Study: 16583424

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15253720

Group type: EXPERIMENTAL
Intervention: Disector/Fractionator method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weibel-Gomez method
Number of subjects: 0
Study: 11736876

Group type: EXPERIMENTAL
Intervention: Oral artesunate (4 mg kg(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral artemether (4 mg kg(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral artemether (first day of treatment)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral artemether (second day of treatment)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: In vivo parasite clearance and time above the in vitro IC90 for both drugs
Number of subjects: 14
Study: 9245924

Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 ng/kg subcutaneously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Octreotide (0.01 microgram, 0.1 microgram, or 1 microgram subcutaneously thrice a day for three days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8328291

Group type: EXPERIMENTAL
Intervention: Random practice schedule with longer summary KR (KR10)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Blocked practice schedule with KR after each practice trial
Number of subjects: 72

Group type: COMPARATOR
Intervention: Blocked practice schedule with 100% KR
Number of subjects: 72
Study: 3511660

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 29383063

Group type: EXPERIMENTAL
Intervention: 1.5× speed video playback for artifacts quiz
Number of subjects: 54

Group type: COMPARATOR
Intervention: 1.0× speed video playback for artifacts quiz (Control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 1.5× speed video playback for transducers assessment
Number of subjects: 54

Group type: COMPARATOR
Intervention: 1.0× speed video playback for transducers assessment (Control)
Number of subjects: 54
Study: 28598116

Group type: EXPERIMENTAL
Intervention: LE+CC
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: LE+HMG
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: CC+HMG
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: LE+CC+HMG
Number of subjects: 209
Study: 25057119

Group type: EXPERIMENTAL
Intervention: Web-based patient narratives intervention; website usage: 46.1% (119/258).
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Website usage (at least 3 times).
Number of subjects: 571

Group type: COMPARATOR
Intervention: Control group (no website usage).
Number of subjects: 571
Study: 22836479

Group type: EXPERIMENTAL
Intervention: High Atrial Pacing (HAP; basic rate at 70 bpm, dual sensor with optimized slope, overdrive pacing)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low Atrial Pacing (LAP; basic rate at 60 bpm, dual sensor with minimal slope)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: High Atrial Pacing (HAP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low Atrial Pacing (LAP)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both HAP and LAP
Number of subjects: 79
Study: 21188918

Group type: EXPERIMENTAL
Intervention: Fine needle aspirational cytology (FNAC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open surgical biopsy
Number of subjects: 46
Study: 18667086

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000IU 25(OH)D3 per day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 11464141

Group type: EXPERIMENTAL
Intervention: Nevirapine (Group A)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Protease Inhibitor (Group B)
Number of subjects: 106
Study: 9552778

Group type: EXPERIMENTAL
Intervention: bupivacaine + both (i.t. 10 mg bupivacaine + 50 microg neostigmine + 150 microg clonidine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: bupivacaine (i.t. 10 mg bupivacaine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine + neostigmine (i.t. 10 mg bupivacaine + 50 microg neostigmine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine + clonidine (i.t. 10 mg bupivacaine + 150 microg clonidine)
Number of subjects: 80
Study: 7868704

Group type: EXPERIMENTAL
Intervention: Siblings of children with cancer after diagnosis
Number of subjects: 254

Group type: COMPARATOR
Intervention: Matched controls from the Child Health Supplement of the National Health Interview Survey (CHS88)
Number of subjects: 254
Study: 3421598

Group type: EXPERIMENTAL
Intervention: Relapse Prevention treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: No-treatment group (control)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Matched group of inmates (control)
Number of subjects: 44
Study: 31126286

Group type: EXPERIMENTAL
Intervention: IRS + LLIN
Number of subjects: 0

Group type: COMPARATOR
Intervention: IRS
Number of subjects: 0

Group type: COMPARATOR
Intervention: LLIN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 28851065

Group type: EXPERIMENTAL
Intervention: Single dose of 270 μg kg‐1 rFVIIa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of 3×90 μg kg‐1 rFVIIa
Number of subjects: 0
Study: 25285748

Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM) plus optimal medical therapy (OMT)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM) plus optimal medical therapy (OMT) in patients with EFs ranging from 25% to 45%
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Peak VO2
Number of subjects: 428
Study: 22949122

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Dexamethasone + Ibuprofen
Number of subjects: 94
Study: 21448073

Group type: EXPERIMENTAL
Intervention: Dexketoprofen (50 mg) intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (2 mL of 0.9% NaCL) intravenously
Number of subjects: 60
Study: 18279521

Group type: EXPERIMENTAL
Intervention: QIRC strategy (experimental group)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Normal practice environment (control group)
Number of subjects: 672
Study: 16023828

Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) cell activity in patients with major depressive disorder
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Circulating levels of interleukin‐6 (IL‐6) in patients with major depressive disorder
Number of subjects: 25

Group type: COMPARATOR
Intervention: Natural Killer (NK) cell activity in controls
Number of subjects: 25

Group type: COMPARATOR
Intervention: Circulating levels of interleukin‐6 (IL‐6) in controls
Number of subjects: 25
Study: 12830447

Group type: EXPERIMENTAL
Intervention: Home hemodialysis (HD) with the Fresenius 2008H machine and Service Deionization Tank (SDI) water treatment system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Home hemodialysis (HD)
Number of subjects: 20
Study: 10854552

Group type: EXPERIMENTAL
Intervention: Cisplatin-based cyclic balloon-occluded arterial infusion chemotherapy (BOAI)
Number of subjects: 18
Study: 9086690

Group type: EXPERIMENTAL
Intervention: diet plus aerobic training
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: diet plus strength training
Number of subjects: 128

Group type: COMPARATOR
Intervention: diet alone
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: diet combined with aerobic and strength training
Number of subjects: 128
Study: 8464671

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (20 mg) aerosolized every 6 hours starting on the first day of intubation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo aerosolized every 6 hours starting on the first day of intubation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 38
Study: 31268250

Group type: EXPERIMENTAL
Intervention: GSK256073 5 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GSK256073 50 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GSK256073 150 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30572911

Group type: EXPERIMENTAL
Intervention: PCG‐lncRNA signature
Number of subjects: 233
Study: 27010201

Group type: EXPERIMENTAL
Intervention: Aroma foot massage
Number of subjects: 57
Study: 24533608

Group type: EXPERIMENTAL
Intervention: DBCare
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 23091096

Group type: EXPERIMENTAL
Intervention: Intensified treatment (chemotherapy every 14 days)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Standard treatment (chemotherapy every 21 days)
Number of subjects: 568
Study: 20303095

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17997459

Group type: EXPERIMENTAL
Intervention: Epirubicin (50 mg instillation)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Epirubicin (recurrences)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo (recurrences)
Number of subjects: 404
Study: 16333652

Group type: EXPERIMENTAL
Intervention: 0.62 g/kg alcohol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0 g/kg)
Number of subjects: 30
Study: 12893041

Group type: EXPERIMENTAL
Intervention: Quiet stance behavior in elderly adults
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quiet stance behavior in young adults
Number of subjects: 20
Study: 11082368

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood cardioplegia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normothermic blood cardioplegia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold blood with warm reperfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined antegrade and retrograde cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antegrade cardioplegia
Number of subjects: 0